20 March 2024
20 March 2024
The trial data will support the US marketing authorisation of Nyxoah’s Genio hypoglossal nerve stimulation system for treating obstructive sleep apnoea.
Gynica is developing the cannabinoid-based candidates IntraVagS301 and IntraVagS302 to alleviate symptoms of endometriosis.
Coming ahead of a planned pre-market approval to the FDA, the topline results found that Cerus’ blood system saw only a 2.5% rate of adverse events.
The SPOTLIGHT study’s primary endpoints are to assess the safety and tolerability of briquilimab in approximately 15 patients.
VCT will aid in verifying research subjects under the deal, curtailing the chances of duplicate enrolment across studies.
The open-label trial is designed to assess the safety and tolerability of Deltacel plus radiotherapy in NSCLC patients.
TwinRCT 3.0 will now have additional historical trial data to improve Phase II trial evaluations.
Reece’s pipeline includes three synthetic polymer anti-infectives for bacteria and viruses.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
